used CAIX CAR-T in a phase I/II clinical trial for renal cancer, and the results showed that plasma levels of interferon (IFN)-γ, interleukin (IL)-2, and tumor necrosis factor-α increased in most patients, but no clinical efficacy was observed.12 The gene discussed is IFNG; the disease is renal carcinoma.